GlassScriptPhysician profile
Kathryn L Mcmullan
NPI 1518164490
$10,117.74
in general payments reported to CMS, 2019-2025
30 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $703 · 2021: $966 · 2022: $1,005 · 2023: $2,756 · 2024: $1,905 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,241 · Consulting Fee: $1,300 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,241.33 |
| Consulting Fee | $1,300.00 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,802.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,774.94 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,364.99 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $609.60 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $422.93 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $401.76 | 2019-2025 | |
| Genzyme Corporation | $272.83 | 2019-2025 | |
| Grifols USA, LLC | $215.31 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Kaleo, INC. | $141.61 | 2020-2022 | |
| Octapharma USA, INC. | $122.28 | 2023-2025 | Panzyga, Cutaquig, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $107.06 | 2020-2024 | Cuvitru |
| Teva Pharmaceuticals USA, INC. | $103.34 | 2020-2021 | |
| Ionis Pharmaceuticals, INC. | $99.97 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.65 | 2020-2022 | |
| Amgen INC. | $67.19 | 2022-2024 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.09 | 2020-2024 | |
| Ars Pharmaceuticals Operations, INC. | $52.86 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $50.51 | 2021-2022 | |
| Uswm, LLC | $50.00 | 2021 | |
| Leo Pharma INC. | $48.66 | 2023 | Adbry |
| Alk-Abello, INC | $38.15 | 2019-2022 | |
| Optinose US, INC. | $36.85 | 2019 | |
| Abbvie INC. | $33.34 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $32.02 | 2025 | Alvesco |
| Incyte Corporation | $28.44 | 2022 | |
| Biocryst US Sales Co., LLC | $27.75 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $24.41 | 2021 | |
| Pharming Healthcare, INC. | $21.46 | 2025 | Ruconest |
| Biocryst Pharmaceuticals, INC. | $17.09 | 2020 | |
| Hikma Pharmaceuticals USA | $14.57 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Mcmullan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.